One-third of target group now vaccinated against monkeypox 10,440 monkeypox vaccinations have already been administered in the Netherlands in the last few weeks. That represents about one-third of the target group currently eligible to get the vaccine against monkeypox. Science Photo Library / ANP
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
WHO Chemical Risk Assessment Workshop on new and emerging risks to human health from chemicals RIVM is hosting an international workshop on new and emerging risks from chemicals on 20 and 21 February 2019.
Possible health risks due to exposure to chromium-6 at tROM project Tilburg Research by RIVM shows that the participants in the so-called tROM project, their supervisors and other people involved may have been exposed to chromium-6.
Kick off European Project VITAL: Vaccines and InfecTious diseases in the Ageing popuLation Recently, the EU-sponsored Vaccines and InfecTious diseases in the Ageing popuLation (VITAL) project was launched.
INHERIT Model: a tool to jointly improve health, environmental sustainability and Health Equity RIVM is involved in the Horizon2020 project INHERIT. The first article of the INHERIT project has been published, lead-authored by RIVM.
RIVM supports WHO in national capacity building for measuring foodborne disease burden RIVM’s Collaborating Centre for Risk Assessment of Pathogens in Food and Water was invited to WHO’s side event during the 41st Codex Alimentarius Commission on July 4th 2018.
Animal-free innovations in safety assessment of chemicals How can the process of validation, acceptance and use of animal-free innovative approaches to assess the safety of chemicals be facilitated?